MX2023001274A - Sintesis quiral de inhibidores de raf biciclicos fusionados. - Google Patents
Sintesis quiral de inhibidores de raf biciclicos fusionados.Info
- Publication number
- MX2023001274A MX2023001274A MX2023001274A MX2023001274A MX2023001274A MX 2023001274 A MX2023001274 A MX 2023001274A MX 2023001274 A MX2023001274 A MX 2023001274A MX 2023001274 A MX2023001274 A MX 2023001274A MX 2023001274 A MX2023001274 A MX 2023001274A
- Authority
- MX
- Mexico
- Prior art keywords
- fused bicyclic
- chiral synthesis
- raf inhibitors
- tautomer
- stereoisomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/821—Ruthenium
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063057531P | 2020-07-28 | 2020-07-28 | |
| PCT/EP2021/071219 WO2022023450A1 (en) | 2020-07-28 | 2021-07-28 | Chiral synthesis of fused bicyclic raf inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001274A true MX2023001274A (es) | 2023-04-24 |
Family
ID=77564067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001274A MX2023001274A (es) | 2020-07-28 | 2021-07-28 | Sintesis quiral de inhibidores de raf biciclicos fusionados. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220041595A1 (https=) |
| EP (1) | EP4188923A1 (https=) |
| JP (1) | JP7832924B2 (https=) |
| KR (1) | KR20230058630A (https=) |
| CN (1) | CN116348465B (https=) |
| AU (1) | AU2021318923A1 (https=) |
| CA (1) | CA3187393A1 (https=) |
| IL (1) | IL300110A (https=) |
| MX (1) | MX2023001274A (https=) |
| WO (1) | WO2022023450A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023535790A (ja) | 2020-07-28 | 2023-08-21 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 縮合二環式ｒａｆ阻害薬及びその使用方法 |
| CN114921508B (zh) * | 2022-07-22 | 2022-10-11 | 常熟药明康德新药开发有限公司 | (r)-6-羟基色满-3-羧酸的生物催化制备方法 |
| JP2025539426A (ja) | 2022-11-29 | 2025-12-05 | ジャズ ファーマシューティカルズ アイルランド リミテッド | （ｓ）－５－（（３－（４－（４－フルオロフェニル）－１ｈ－イミダゾール－２－イル）クロマン－６－イル）オキシ）－３，４－ジヒドロ－１，８－ナフチリジン－２（１ｈ）－オンの結晶形態 |
| EP4665725A2 (en) * | 2023-02-17 | 2025-12-24 | Jazz Pharmaceuticals Ireland Limited | Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3932657A (en) | 1973-11-12 | 1976-01-13 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome encapsulation of chelating agents |
| GB1575343A (en) | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452747A (en) | 1982-03-22 | 1984-06-05 | Klaus Gersonde | Method of and arrangement for producing lipid vesicles |
| JPS6058915A (ja) | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | 薬物含有脂質小胞体製剤 |
| US4744989A (en) | 1984-02-08 | 1988-05-17 | E. R. Squibb & Sons, Inc. | Method of preparing liposomes and products produced thereby |
| US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4830858A (en) | 1985-02-11 | 1989-05-16 | E. R. Squibb & Sons, Inc. | Spray-drying method for preparing liposomes and products produced thereby |
| US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| JPH0617309B2 (ja) | 1985-11-29 | 1994-03-09 | 株式会社ビタミン研究所 | アドリアマイシン包埋リポソ−ム製剤 |
| DE3611229A1 (de) | 1986-04-04 | 1987-10-08 | Basf Ag | Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinoidpraeparaten |
| MX9203808A (es) | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5766635A (en) | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
| DE69529054T2 (de) | 1994-02-28 | 2003-08-21 | Nanopharm Ag | System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| EP0825852B1 (en) | 1995-04-18 | 2004-07-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposome drug-loading method and composition |
| US8137699B2 (en) | 2002-03-29 | 2012-03-20 | Trustees Of Princeton University | Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2462376C (en) | 2001-10-03 | 2010-12-14 | Celator Technologies Inc. | Liposome loading with metal ions |
| CA2467064C (en) | 2001-11-13 | 2011-02-08 | Murray Webb | Lipid carrier compositions with enhanced blood stability |
| LT2653465T (lt) * | 2004-03-15 | 2016-09-12 | Janssen Pharmaceutica Nv | Opioidinio receptoriaus moduliatoriai |
| JP5001263B2 (ja) * | 2005-05-20 | 2012-08-15 | ドクター レディズ ラボラトリーズ （イーユー） リミテッド | ジフェニルアラニン誘導体作製のための不斉水素化 |
| GB201416186D0 (en) * | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
| CN109503659B (zh) * | 2019-01-03 | 2021-06-18 | 凯特立斯（深圳）科技有限公司 | 氧杂螺环双膦配体及其在α,β-不饱和羧酸不对称氢化中的应用 |
-
2021
- 2021-07-28 WO PCT/EP2021/071219 patent/WO2022023450A1/en not_active Ceased
- 2021-07-28 EP EP21763010.2A patent/EP4188923A1/en active Pending
- 2021-07-28 AU AU2021318923A patent/AU2021318923A1/en active Pending
- 2021-07-28 KR KR1020237006990A patent/KR20230058630A/ko active Pending
- 2021-07-28 CA CA3187393A patent/CA3187393A1/en active Pending
- 2021-07-28 CN CN202180064843.6A patent/CN116348465B/zh active Active
- 2021-07-28 JP JP2023505376A patent/JP7832924B2/ja active Active
- 2021-07-28 MX MX2023001274A patent/MX2023001274A/es unknown
- 2021-07-28 IL IL300110A patent/IL300110A/en unknown
- 2021-07-28 US US17/387,041 patent/US20220041595A1/en not_active Abandoned
-
2025
- 2025-07-14 US US19/268,592 patent/US20260049079A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4188923A1 (en) | 2023-06-07 |
| KR20230058630A (ko) | 2023-05-03 |
| CN116348465A (zh) | 2023-06-27 |
| CA3187393A1 (en) | 2022-02-03 |
| WO2022023450A1 (en) | 2022-02-03 |
| CN116348465B (zh) | 2026-04-17 |
| JP2023535595A (ja) | 2023-08-18 |
| JP7832924B2 (ja) | 2026-03-18 |
| US20220041595A1 (en) | 2022-02-10 |
| AU2021318923A1 (en) | 2023-03-09 |
| IL300110A (en) | 2023-03-01 |
| US20260049079A1 (en) | 2026-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001274A (es) | Sintesis quiral de inhibidores de raf biciclicos fusionados. | |
| CR20220354A (es) | Inhibidores de egfr | |
| MX2023010429A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). | |
| PH12021552805A1 (en) | Cdk inhibitors | |
| TN2018000319A1 (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| PH12022551014A1 (en) | Substituted tricyclic compounds | |
| MX2023000333A (es) | Sales y formas de un inhibidor wee1. | |
| MX2024000230A (es) | Inhibidores de cdk2. | |
| SG10201903532XA (en) | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor | |
| MY155653A (en) | Triazine compounds as p13 kinase and mtor inhibitors | |
| MY147440A (en) | Process for making 3-substituted 2-amino-5-halobenzamides | |
| MY206521A (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| EA201170617A1 (ru) | Пиразолиламинопиридины в качестве ингибиторов fak | |
| NZ710411A (en) | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) | |
| IN2014KN01030A (https=) | ||
| CR20240014A (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| MX2023001275A (es) | Inhibidores de raf biciclicos fusionados y metodos para su uso. | |
| EA201891437A1 (ru) | Способ разделения энантиомеров пиперазиновых производных | |
| EA201100696A1 (ru) | 1-(арилсульфонил)-4-(пиперазин-1-ил)-1h-бензимидазолы в качестве лигандов 5-гидрокситриптамина-6 | |
| PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
| MX2024012267A (es) | Inhibidores de egfr | |
| AU2020298092A8 (en) | Process for the preparation of CIC-1 chloride channel inhibitors | |
| MX2023010606A (es) | Formas de sales y sólidas de un inhibidor de cinasas. | |
| MX2021015418A (es) | Terapia inmunooncologica. |